Cavit PM Tablet 15s

Cavit PM Tablet 15s is an oral combination of bone-supportive minerals, a fat-soluble vitamin, and phytoestrogenic compounds that collectively maintain skeletal integrity and address the hormonal and nutritional drivers of menopausal bone loss.

Elemental calcium is the primary mineral constituent of hydroxyapatite, the crystalline matrix providing structural rigidity to bone. In post-menopausal women, oestrogen withdrawal accelerates osteoclast-mediated bone resorption, increasing daily calcium requirements. Supplemental calcium maintains positive calcium balance, reducing the stimulus for parathyroid hormone-mediated cortical bone resorption.

Magnesium hydroxide provides bioavailable magnesium, an essential cofactor for bone matrix formation and vitamin D activation. Approximately sixty percent of total body magnesium is stored in bone, influencing hydroxyapatite crystal size and stability. Magnesium is required for the hepatic and renal hydroxylation steps converting cholecalciferol to its active form, calcitriol. Deficiency independently impairs vitamin D activation and increases fracture risk.

Vitamin D3 (cholecalciferol) undergoes hepatic 25-hydroxylation and renal 1-alpha-hydroxylation to form calcitriol, which binds the vitamin D receptor in intestinal enterocytes, upregulating calcium-binding protein synthesis and increasing active calcium and phosphate absorption. Vitamin D insufficiency is highly prevalent in post-menopausal women and directly impairs calcium absorption efficiency.

Isoflavones are polyphenolic phytoestrogens derived principally from soya, structurally similar to 17-beta-oestradiol. They bind oestrogen receptors with preferential affinity for oestrogen receptor beta expressed in bone tissue, stimulating osteoblast activity and inhibiting osteoclast differentiation. This provides oestrogen-like skeletal protection without the systemic hormonal effects of conventional hormone replacement therapy.

Together, these four components address calcium and magnesium supply, vitamin D-mediated absorption efficiency, and oestrogen receptor-mediated anti-resorptive signalling in bone.

The uses of Cavit PM Tablet 15s are as follows:

Post-Menopausal Osteoporosis Prevention

Cavit PM Tablet 15s reduces bone mineral density loss in post-menopausal women by addressing oestrogen withdrawal, calcium insufficiency, and vitamin D deficiency simultaneously.

Peri-Menopausal Bone Loss

Used during the peri-menopausal transition to maintain bone mineral density during the period of accelerating oestrogen-related bone resorption.

Calcium and Vitamin D Deficiency

Corrects nutritional deficiencies of calcium, magnesium, and vitamin D contributing to impaired bone mineralisation and increased fracture risk.

Menopausal Symptom Support

Isoflavones may provide mild oestrogen receptor-mediated reduction of vasomotor symptoms including hot flushes in some women.

Adjunctive Bone Support in Osteopenia

Used alongside lifestyle measures and pharmacological treatment to support bone health in patients with osteopenia on dual-energy X-ray absorptiometry.

Here are the benefits of Cavit PM Tablet 15s :

• Comprehensive Bone Mineralisation Support: Provides calcium and magnesium in bioavailable forms alongside vitamin D3, ensuring the full mineral substrate and absorptive capacity required for bone matrix maintenance.

• Phytoestrogenic Anti-Resorptive Action: Isoflavones reduce osteoclast activity through oestrogen receptor beta activation, providing targeted skeletal protection without systemic hormonal effects.

• Enhanced Calcium Absorption: Vitamin D3 upregulates intestinal calcium transport, maximising bioavailability of supplemental calcium and magnesium.

• HRT-Free Bone Protection: Suitable for post-menopausal women in whom hormone replacement therapy is contraindicated, declined, or not yet warranted.

• Musculoskeletal and Neuromuscular Support: Calcium, magnesium, and vitamin D collectively support muscle contractility and neuromuscular function, reducing fall risk and secondary fracture incidence.

Like all medicines, Cavit PM Tablet 15s may cause side effects in some individuals.

Common Side Effects

• Constipation: Calcium supplementation commonly causes constipation, particularly at higher doses; adequate fluid and dietary fibre intake helps minimise this effect.

• Gastrointestinal Discomfort: Bloating, flatulence, or mild nausea may occur, particularly when taken on an empty stomach.

• Altered Bowel Habit: Magnesium hydroxide has a mild laxative effect that may counterbalance calcium-related constipation but may cause loose stools in some individuals.

Uncommon Side Effects

• Hypercalcaemia: Excessive calcium intake may elevate serum calcium, causing fatigue, confusion, polyuria, and constipation, particularly in patients with underlying hyperparathyroidism.

• Headache: Mild headache may occur during initiation of supplementation.

• Nausea: Particularly associated with higher doses of magnesium hydroxide.

Serious Side Effects (Require Immediate Medical Attention)

• Severe Hypercalcaemia: Markedly elevated serum calcium causing confusion, cardiac arrhythmias, or renal impairment requires urgent medical review and temporary discontinuation.

• Vitamin D Toxicity: Excessive vitamin D3 intake causes hypercalcaemia and hypercalciuria with risk of nephrocalcinosis and renal stones; avoid concurrent high-dose vitamin D supplements.

• Severe Allergic Reaction: Swelling of the face, lips, or throat with difficulty breathing requires urgent medical care.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Usually taken orally once or twice daily with food to improve calcium absorption and reduce gastrointestinal discomfort.

• Take with adequate fluid to reduce constipation risk.

• Do not exceed the prescribed dose, particularly for calcium and vitamin D.

• Do not discontinue without consulting your doctor.

Cavit PM Tablet 15s supports bone health through four complementary mechanisms addressing mineral availability, absorptive capacity, and hormonal bone remodelling balance.

Elemental calcium directly supplies ionic calcium required for hydroxyapatite crystal deposition in the bone matrix. Maintaining positive calcium balance reduces parathyroid hormone secretion, which would otherwise mobilise calcium from cortical bone and accelerate resorption.

Vitamin D3 undergoes sequential hydroxylation to form calcitriol, which binds the nuclear vitamin D receptor in intestinal epithelial cells, inducing calbindin-D9k and the TRPV6 calcium channel, increasing active calcium transport across the intestinal mucosa.

Magnesium hydroxide supplies magnesium required as a cofactor for the renal 25-hydroxyvitamin D 1-alpha-hydroxylase enzyme, ensuring efficient calcitriol production and influencing hydroxyapatite crystal structure and bone quality.

Isoflavones, following intestinal absorption, bind preferentially to oestrogen receptor beta in osteoblasts and osteoclast precursors, stimulating bone formation gene expression and inhibiting RANKL-mediated osteoclast differentiation, shifting the bone remodelling balance towards formation.

A few practical measures can help improve treatment outcomes and ensure safe use of Cavit PM Tablet 15s :

• Take with food: Calcium absorption is optimised in the presence of gastric acid stimulated by food, and taking with meals reduces gastrointestinal discomfort from magnesium hydroxide.

• Avoid concurrent high-dose calcium supplements: Total daily calcium from all sources should be assessed; excessive intake increases hypercalcaemia and renal stone risk without additional bone benefit.

• Monitor serum calcium and vitamin D periodically: Regular blood tests ensure levels remain within the therapeutic range and prevent silent hypercalcaemia with long-term use.

• Combine with weight-bearing exercise: Regular weight-bearing activity acts synergistically with this formulation to stimulate osteoblast activity and maintain bone density.

• Ensure adequate sun exposure where safe: Moderate sunlight exposure supports endogenous vitamin D3 synthesis and complements supplemental cholecalciferol.

Proper storage is important to maintain the stability and effectiveness of Cavit PM Tablet 15s :

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep in original packaging: Protects tablets from humidity and light degradation, particularly relevant for vitamin D3 stability.

• Keep out of reach of children: Store safely to prevent accidental ingestion.

• Check expiry before use: Do not use after the expiry date printed on the packaging.

Cavit PM Tablet 15s may be affected by dietary habits. The following should be noted:

• Take with food: Enhances calcium absorption and reduces gastrointestinal discomfort from magnesium hydroxide.

• Avoid high-phytate or high-oxalate foods at time of dosing: Phytates in wholegrains and oxalates in spinach bind calcium in the gastrointestinal tract, reducing absorption; separate the dose from such foods where possible.

• Limit alcohol intake: Alcohol reduces calcium absorption, impairs vitamin D metabolism, and accelerates bone loss, directly counteracting the benefit of this combination.

Cavit PM Tablet 15s may interact with the following medicines:

• Bisphosphonates: Calcium and magnesium bind bisphosphonates in the gastrointestinal tract, markedly reducing their absorption; separate dosing by at least two hours, taking bisphosphonates on an empty stomach before this formulation.

• Thiazide Diuretics: Thiazides reduce urinary calcium excretion, potentially compounding calcium supplementation to cause hypercalcaemia; calcium levels should be monitored.

• Tetracycline and Quinolone Antibiotics: Divalent cations including calcium and magnesium chelate these antibiotics, reducing their absorption; separate dosing by at least two to three hours.

• Levothyroxine: Calcium supplements reduce levothyroxine absorption when taken concurrently; separate dosing by at least four hours.

• Corticosteroids: Prolonged corticosteroid use impairs intestinal calcium absorption and increases bone resorption, making this combination particularly relevant as adjunctive support but requiring careful monitoring of calcium and vitamin D levels.

Cavit PM Tablet 15s should be used carefully in the following conditions:

• Hypercalcaemia: Pre-existing elevated serum calcium contraindicates additional calcium and vitamin D supplementation until the underlying cause is managed.

• Nephrolithiasis: Calcium supplementation may increase urinary calcium excretion and stone formation risk in calcium oxalate stone formers; adequate hydration and medical supervision are essential.

• Sarcoidosis and Granulomatous Diseases: These conditions cause autonomous vitamin D activation, making patients highly sensitive to hypercalcaemia with even modest supplementation; use only under specialist supervision.

• Hormone-Sensitive Cancers: Isoflavones exert oestrogen receptor activity; use in patients with oestrogen receptor-positive breast or endometrial cancer should only proceed under oncological review.

• Primary Hyperparathyroidism: Elevated PTH with hypercalcaemia contraindicates calcium supplementation until the underlying condition is managed.

Usually taken once or twice daily with food as directed by your doctor. The specific dose depends on formulation strength, individual dietary calcium intake, serum vitamin D levels, and clinical indication. Total daily calcium intake from diet and supplements combined should not routinely exceed 2000 mg. Always follow your doctor's prescription.

If a dose is missed, take it as soon as remembered. Do not double the dose to make up for a missed one. Maintain the regular schedule thereafter.